Delivery Order 75F40121D00018-75F40121F19001
Award Date 8/2/21
Potential Completion Date 8/5/26
Potential Value $2M
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at one hundred thousand dollars from the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide currently marketed drug products for FDA research studies. This order was issued against the company's existing five-year, nine and a half million dollar contract awarded in 2020 by HHS FDA to supply drug products for internal research in support of the...
- The Food and Drug Administration (FDA) awarded a delivery order valued at $300,000 to We Pharma, Inc., doing business as WEP Clinical, for the provision of pharmaceutical drug products to support FDA research studies. The contract, which is firm fixed price with no set-aside designation, carries an ultimate completion date of September 16, 2026, and will be performed at the FDA's Takoma Park, Maryland location. We Pharma, a self-certified small disadvantaged business and limited liability...
- This firm-fixed-price purchase order was awarded by the Food and Drug Administration (FDA), a civilian agency under the Department of Health and Human Services, to We Pharma, Inc., a self-certified small disadvantaged business. The $214,914.90 contract is for the provision of "PHYSICOCHEMICAL PRODUCTS" and has a total small business set-aside. The award supports the FDA's regulatory science program and provides pharmaceutical drug products for the agency's research, compliance, and...
- This is a delivery order awarded by the Food and Drug Administration (FDA) to We Pharma, Inc., a self-certified small disadvantaged business structured as a limited liability company. The contract, valued at $357,000.00, is for the provision of pharmaceutical drug products to support the FDA's various research, regulatory, and emergency response activities. We Pharma, doing business as WEP Clinical, holds two significant Indefinite Delivery Contracts (IDCs) with the FDA, totaling $9.5 million...
- This is a firm-fixed-price delivery order awarded to We Pharma, Inc., a self-certified small disadvantaged business, by the Food and Drug Administration (FDA) under an Indefinite Delivery Contract (IDC). The purpose of this $399,561.18 award is to provide pharmaceutical drug products to support the FDA's research studies, regulatory activities, and emergency response needs. The contract has an ultimate completion date of August 6, 2024. This delivery order is not set-aside and is part of two...
- This firm-fixed-price purchase order contract was awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to We Pharma, Inc., doing business as WEP Clinical. The contract, valued at $197,000.00, is for the procurement of pharmaceutical drug products to support the FDA's Center for Drug Evaluation and Research (CDER) research and regulatory activities. WEP Clinical, a self-certified small disadvantaged business, specializes...
- This delivery order against the Department of Health and Human Services Food and Drug Administration is for the purpose of obtaining currently marketed drug products for FDA research studies. Awarded on September 30, 2020 to We Pharma, Inc. located in Morrisville, North Carolina, this firm fixed price contract has a potential value of $246,754.22 and period of performance through September 29, 2021. No set-aside designation was applied. We Pharma Inc. will provide the requested drug products...
- The Department of Health and Human Services Food and Drug Administration awarded a $169,918.01 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. We Pharma will provide the requested products to the FDA under this contract, which has a completion date of September 29, 2021. No set-aside designation was used for this award made on September 30, 2020.
- The Department of Health and Human Services Food and Drug Administration awarded a $145,636.17 firm fixed price delivery order to We Pharma, Inc. of Silver Spring, Maryland for pharmaceutical products to support domestic manufacturing. No set-aside provisions were applied to this contract. We Pharma will provide the FDA's Office of Pharmaceutical Quality with domestic pharmaceutical manufacturing supplies through September 30th, 2022 at their Silver Spring location. As the regulatory body...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed-price purchase order to The Pharma Letter LIMITED, a for-profit organization, for a $113,008.00 pharmaceutical subscription for 25 users. The contract has a performance period ending May 20, 2025, with an award date of May 20, 2020. The subscription provides the FDA's Office of Global Policy and Strategy (OGPS) staff with access to global news, expert commentary, and analysis on pharmaceutical, generic,...